Boston Scientific CorporationBSXNYSE
Loading
Operating Cash Flow Growth Under PressureDecelerating
Percentile Rank36
3Y CAGR-72.1%
5Y CAGR-19.6%
Year-over-Year Change
Year-over-year operating cash flow growth rate
3Y CAGR
-72.1%/yr
vs -0.1%/yr prior
5Y CAGR
-19.6%/yr
Recent deceleration
Acceleration
-72.0pp
Decelerating
Percentile
P36
Within normal range
vs 5Y Ago
0.3x
Contraction
Streak
2 qtr
Consecutive declineDecelerating
| Period | Value |
|---|---|
| Q4 2025 | 1.56% |
| Q3 2025 | 4.43% |
| Q2 2025 | 137.71% |
| Q1 2025 | -62.84% |
| Q4 2024 | 45.31% |
| Q3 2024 | 23.25% |
| Q2 2024 | 395.73% |
| Q1 2024 | -82.86% |
| Q4 2023 | 37.11% |
| Q3 2023 | 6.08% |
| Q2 2023 | 246.32% |
| Q1 2023 | -76.46% |
| Q4 2022 | 71.70% |
| Q3 2022 | 53.09% |
| Q2 2022 | 629.31% |
| Q1 2022 | -112.13% |
| Q4 2021 | 2.80% |
| Q3 2021 | -27.68% |
| Q2 2021 | 126.41% |
| Q1 2021 | -57.80% |
| Q4 2020 | 4.67% |
| Q3 2020 | 139.03% |
| Q2 2020 | 449.35% |
| Q1 2020 | -111.13% |
| Q4 2019 | 37.85% |
| Q3 2019 | 71.92% |
| Q2 2019 | -16.57% |
| Q1 2019 | 1742.11% |
| Q4 2018 | -96.21% |
| Q3 2018 | 224.32% |
| Q2 2018 | -308.81% |
| Q1 2018 | -77.87% |
| Q4 2017 | 92.92% |
| Q3 2017 | 52.19% |
| Q2 2017 | 4342.86% |
| Q1 2017 | -101.50% |
| Q4 2016 | 1603.23% |
| Q3 2016 | -107.36% |
| Q2 2016 | 262.93% |
| Q1 2016 | -64.74% |